News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Immutep.
RELATED STOCKHEAD STORIES
News
ASX Small Cap Lunch Wrap: Who’s dodging bullets today?
Health & Biotech
Immutep’s cancer-fighting drug candidate efti shows early promise
News
10 at 10: These ASX stocks have imposed their presence this morning
Health & Biotech
Aged care operator Estia falls to loss as COVID-19 costs bite
Health & Biotech
Health: Immutep has dosed the last patient in one of its cancer studies
Health & Biotech
Selvax cures cancer in dogs, says it’s eyeing an IPO
Health & Biotech
ATO blocks biotech access to Jobkeeper wage subsidy
Health & Biotech
Check up: COVID-19 still sells but investors are looking for the next endorphin hit
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Pharmaxis forges ahead with phase 2 cancer drug trial in spite of COVID-19
Health & Biotech
Cancer clinical trials continue as others are shut down on COVID-19 fears
Health & Biotech
Cyclopharm says radioactive gas could help diagnose COVID-19
Health & Biotech
Health Kick Podcast: Understanding immunotherapy, why the drug market dried up and Immutep’s profitable potential
Health & Biotech
Health: Medlab proves pot reduces a very specific kind of cancer pain
Health & Biotech
Dr Boreham’s Crucible: Investors hawk-eyed as Immutep closes in on breast cancer drug results
Health & Biotech
Biotech: It’s not a get-rich-quick scheme judging by these HY reports
Health & Biotech
